MedTrace Logo

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

NCT07318389 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-27

No results posted yet for this study

Summary

To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

Conditions

Interventions

OTHER

SOC (Standard of care)

Blood draws, biopsies, samples and MRI.

DRUG

Bevacizumab

Given by IV

DRUG

Cetuximab

Given by Iv

DRUG

Panitumumab

Given by Iv

DRUG

FOLFIRI

Given by Iv

DRUG

FOLFOX

Given by Iv

DRUG

Encorafenib

Given by po

DRUG

Adagrasib

Given by Po

DRUG

Trifluridine/tipiracil (TAS-102)

Given by po

DRUG

Trastuzumab deruxtecan

Given by IV

DRUG

Tucatinib

Given by po

DRUG

Sotorasib

Given by po

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Scott Kopetz, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-10
Primary Completion
2027-11-14
Completion
2029-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07318389 on ClinicalTrials.gov